BiomX Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of
	September 30, 2024	December 31, 2023
ASSETS
Current assets
Cash and cash equivalents	23,537	14,907
Restricted cash	1,114	957
Other current assets	3,665	1,768
Total current assets	28,316	17,632
Non-current assets
Other assets	96	-
Operating lease right-of-use assets	9,700	3,495
Property and equipment, net	6,581	3,902
In-process Research and development (“IPR&D”) assets	15,287	-
Total non-current assets	31,664	7,397
	59,980	25,029

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of
	September 30, 2024	December 31, 2023
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Trade accounts payable	2,779	1,381
Current portion of lease liabilities	1,096	666
Other accounts payable	5,069	3,344
Current portion of long-term debt	-	5,785
Total current liabilities	8,944	11,176
Non-current liabilities
Contract liability	-	1,976
Long-term debt, net of current portion	-	5,402
Operating lease liabilities, net of current portion	8,651	3,239
Other liabilities	161	155
Private Placement Warrants	4,328	-
Total non-current liabilities	13,140	10,772
Commitments and Contingencies (Note 7)
Stockholders’ equity
Preferred Stock, $0.0001 par value; Authorized – 1,000,000 shares as of September 30, 2024 and December 31, 2023. Issued and outstanding- 147,735 as of September 30, 2024. No shares issued and outstanding as of December 31, 2023.	18,645	-
Common Stock, $0.0001 par value; Authorized – 750,000,000 shares as of September 30, 2024 and 120,000,000 shares as of December 31, 2023. Issued and outstanding- 18,176,602 shares as of September 30, 2024 and 4,723,320 shares as of December 31, 2023. (*)	6	3
Additional paid in capital	185,429	166,048
Accumulated deficit	(166,184)	(162,970)
Total stockholders’ equity	37,896	3,081
	59,980	25,029

(*)	All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.